<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109423">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02112864</url>
  </required_header>
  <id_info>
    <org_study_id>dexaPTPS</org_study_id>
    <nct_id>NCT02112864</nct_id>
  </id_info>
  <brief_title>Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome</brief_title>
  <official_title>Impact of Dexamethasone on the Post Operative Inflammatory Response and on the Occurrence of Post Thoracotomy Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <authority>Canada: Ministère santé et services sociaux du Québec</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post thoracotomy pain syndrome still affects 50% of patients after a thoracic surgery.
      Pathogenesis is unclear but there is growing evidence that neuro inflammation may play a
      significant role.  Dexamethasone is a very potent anti-inflammatory drug.  The hypothesis of
      this study is that dexamethasone, given pre operatively, would help reduce the incidence of
      post thoracotomy pain syndrome 3 months after surgery, by reducing the inflammatory
      response, in patients undergoing elective thoracic surgery that includes thoracic epidural
      analgesia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>incidence of post thoracotomy pain syndrome</measure>
    <time_frame>three months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>cytokine elevation</measure>
    <time_frame>1, 24 and 48h after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of post thoracotomy pain syndrome</measure>
    <time_frame>6 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incisional and shoulder pain</measure>
    <time_frame>acute post operative period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief pain inventory questionnaire</measure>
    <time_frame>three months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief pain inventory questionnaire</measure>
    <time_frame>6 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leeds Assessment of Neuropathic Signs and Symptoms questionnaire</measure>
    <time_frame>three and six months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Pain</condition>
  <condition>Dexamethasone</condition>
  <condition>Thoracic Surgery</condition>
  <condition>Cytokines</condition>
  <arm_group>
    <arm_group_label>dexamethasone 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single-dose, pre incision, intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>dexamethasone 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective thoracic surgery using a thoracotomy incision and thoracic epidural
             analgesia

          -  ASA I-III

          -  age 18-75 yo

        Exclusion Criteria:

          -  contra-indication to thoracic epidural analgesia

          -  patient refusal

          -  patients already taking cortisone or dexamethasone

          -  patients on chronic opioid medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Véronique Brulotte, MD, MSc</last_name>
    <phone>514 252-3400</phone>
    <phone_ext>4558</phone_ext>
    <email>veronique.brulotte@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia Godin, nurse</last_name>
    <phone>514 252-3400</phone>
    <phone_ext>3193</phone_ext>
    <email>ngodin.hmr.@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 4M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brulotte Veronique, MD, MSc</last_name>
      <phone>514 252-3400</phone>
      <phone_ext>4558</phone_ext>
      <email>veronique.brulotte@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Veronique Brulotte, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Veronique Brulotte</investigator_full_name>
    <investigator_title>M.D., M.Sc.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
